文献速递肝病

HBeAg阴性慢性乙肝停用核苷(酸)类似物的荟萃分析

Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis.
PubMed 文献 · Gut · 2021-09-07

该荟萃分析纳入37项研究,评估HBeAg阴性慢性乙肝患者停用核苷(酸)类似物后的临床结局。停用恩替卡韦/替诺福韦后6个月病毒学复发累积发生率44%、临床复发17%,12个月分别为63%和35%;停药后可出现HBsAg清除,随访更长者清除率更高。

要点

  • 停用恩替卡韦/替诺福韦后12个月病毒学复发累积发生率63%、临床复发35%。
  • 停用旧代核苷(酸)类似物后复发率与停用恩替卡韦/替诺福韦相似。
  • 停药后可见HBsAg清除,随访≥4年与旧代药物停药后HBsAg清除率相关。

核心结论

  • 停用核苷(酸)类似物后病毒学复发常见,但12个月时临床复发仅见于约三分之一患者。
  • 停药后可出现HBsAg清除,且随访时间越长清除率越高。

研究设计与样本

  • 荟萃分析,纳入37项关于HBeAg阴性慢性乙肝患者停用核苷(酸)类似物的研究,要求中位随访≥12个月,停药时HBeAg阴性。
  • 采用随机效应模型分析病毒学复发、临床复发和HBsAg清除,并行亚组分析和荟萃回归。

主要发现

  • 停用恩替卡韦/替诺福韦后6个月病毒学复发累积发生率44%、临床复发17%,12个月分别为63%和35%。
  • 停用旧代核苷(酸)类似物后复发率与停用恩替卡韦/替诺福韦相似。
  • 在停用恩替卡韦/替诺福韦的患者中,停用替诺福韦与6个月临床复发率较恩替卡韦增高相关。
  • 停用旧代药物后,随访≥4年与HBsAg清除率之间存在关联。
  • 肝衰竭和肝细胞癌罕见,但在纳入肝硬化患者的研究中发生更频繁。

临床怎么用

  • HBeAg阴性慢性乙肝患者停用核苷(酸)类似物后需密切监测病毒学复发和临床复发。
  • 停药后应长期随访以评估HBsAg清除可能,尤其随访≥4年者。
  • 肝硬化患者停药后肝衰竭和肝细胞癌风险更高,需加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Sustained virological suppression and hepatitis B surface antigen (HBsAg) loss have been described after nucleot(s)ide analogue (NA) discontinuation for patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). We performed a meta-analysis of the clinical outcomes after NA discontinuation for HBeAg-negative CHB. METHODS: Studies involving NA cessation in HBeAg-negative CHB individuals with a median follow-up of ≥12 months were included. Participants were HBeAg-negative at the time of NA initiation. Random effects meta-analyses were performed for the following clinical outcomes: (1) virological relapse (VR) at 6 and 12 months; (2) clinical relapse (CR) at 6 and 12 months and (3) HBsAg loss. Effect of other variables was estimated using subgroup analysis and meta-regression. Studies including patients stopping entecavir (ETV) and/or tenofovir disoproxil fumarate (TDF) were considered separately to studies including patients stopping older generation NA. RESULTS: N=37 studies met inclusion criteria. Cumulative incidence of VR and CR after stopping ETV/TDF was 44% and 17% at 6 months and 63% and 35% at 12 months. Similar relapse rates were observed after stopping older NAs. Among patients stopping ETV/TDF, TDF cessation was associated with increased CR rates at 6 months versus ETV. There was an association between follow-up ≥4 years and HBsAg loss rates when stopping older NAs. Hepatic decompensation and hepatocellular carcinoma were rare but occurred more frequently in studies including cirrhotic individuals. CONCLUSION: VR is common after NA discontinuation, however, CR was only seen in one-third of patients at 12 months. Stopping NA therapy can be followed by HBsAg clearance, and rates are higher with longer follow-up.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Hall SAL, Vogrin S, Wawryk O, et al. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis. Gut. 2021. PMID: 34493592. doi:10.1136/gutjnl-2020-323979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。